Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inobrodib in Combination With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT07772024Phase 3Recruiting
- Sponsor
- CellCentric
- Start
- Aug 2026
- Primary completion
- Nov 2029
- Countries
- 1
01
Overview
A Phase 3 trial of inobrodib in multiple myeloma (MM), sponsored by CellCentric. Started Aug 2026; status: recruiting.
02
Drugs
inobrodib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07772024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07772024.